Table 2.
HLA-DR3-restricted T cell responses and HLA-DR3 binding of 85B-derived peptides in humans or HLA-DR3.Ab0 mice
| 85B amino acid sequence | Recognition by HLA-DR3-restricted T cells*
|
HLA-DR3 binding affinity, IC50 μM† | |
|---|---|---|---|
| In humans | In tg mice | ||
| 34-53 LQVPSPSMGRDIKVQFQSGG | +++ | ++ | 0.4 |
| 154-173 SAMILAAYHPQQFIYAGSLS | − | − | 3 |
| 164-183 QQFIYAGSLSALLDPSQGMG | − | − | 8 |
| 134-153 ANRAVKPTGSAAIGLSMAGS | − | − | 9 |
| 144-163 AAIGLSMAGSSAMILAAYHP | − | − | 15 |
| 284-303 THSWEYWGAQLNAMKGDLQS | − | − | 25 |
| All other peptides | − | − | >100 |
DR3.Ab0 mice were immunized with BCG and Ag85 (10 μg per mouse). After 7 days, LNCs were challenged in vitro with 85B− peptide (50 μg/ml).
*
+++ indicates SI ≥ 4; ++ indicates 3 ≤ SI ≤ 4; − indicates SI < 2.
†
Peptide binding affinity (IC50) was defined as high-affinity (<1 μM), intermediate-affinity (1 μM to 10 μM), weak-affinity (10 μM to 100 μM), or nonbinding (>100 μM), according to ref. 27.